La vendita allo scoperto per Exact Sciences dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Exact Sciences. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Exact Sciences (NASDAQ:EXAS) Azioni, Report sulle vendite allo scoperto

EXACT SCIENCES CORP

Exact Sciences

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Trump’s Economic Gambit Sparks Fierce Debate As Cathie Wood Sees A Reagan-Style Boom, Obama Adviser Calls Musk’s Role A ‘Performance Art’

Equities

News

Markets

ETFs

ARKG

ARKK

ARKW

DKNG

EXAS

GTLB

PATH

RPTX

L&#39;investimento massiccio punta su due società innovative nel settore sanitario e dello sviluppo software. Cosa bolle in pentola?

Ark Invest di Cathie Wood scommette sull&#39;IA: ecco chi ha comprato

Exact Sciences Corporation - Common Stock

Exact Sciences Corp

Exasol AG

Exact Sciences Reports Launch Of Cologuard Plus Colorectal Cancer Screening Test

Analysts' ratings for Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $65.71, along with a high estimate of $73.00 and a low estimate of $52.00. A decline of 6.66% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741870918_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Exact Sciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$52.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$73.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exact Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Exact Sciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Exact Sciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>About Exact Sciences</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Understanding the Numbers: Exact Sciences's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Exact Sciences displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 10.29%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -121.19%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Exact Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -30.81%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Exact Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -13.64%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.15.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts

RBC Capital analyst Gerard Cassidy initiates coverage on Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Sector Perform rating and announces Price Target of $52.

Price Target

Initiation

RBC Capital Initiates Coverage On Exact Sciences with Sector Perform Rating, Announces Price Target of $52

On Friday, Feb. 28, 2025, Cathie Wood&#8217;s&nbsp;Ark Invest&nbsp;made some notable trades. The most prominent among these were the purchases of&nbsp;Archer Aviation Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>),&nbsp;Recursion Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>),&nbsp;Tempus AI Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), and&nbsp;Iridium Communications Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>).
On the other hand, Ark Invest decided to offload shares of&nbsp;Twist Bioscience Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>),&nbsp;Adyen NV&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADYEY#OTC">ADYEY</a>),&nbsp;Accolade Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>), and&nbsp;Exact Sciences Corp&nbsp;(NCM: EXAS).
The ACHR Trade
Ark Invest purchased a significant number of shares in&nbsp;Archer Aviation Inc&nbsp;across three of its ETFs. The ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) bought 360,583 shares, the ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) acquired 54,699 shares, and the ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) added 17,322 shares.
Based on the closing price of $8.88 on Friday, the total value of these trades is approximately $3.8 million.
The RXRX and TEM Trades
Ark Invest also showed a strong interest in&nbsp;Recursion Pharmaceuticals Inc&nbsp;and&nbsp;Tempus AI Inc. Ark Invest <a href="https://www.benzinga.com/markets/equities/25/02/43963343/cathie-woods-buys-the-dip-in-tempus-ai-coinbase-but-sells-arks-bitcoin-etf-shares-amid-crypto-meltdown">previously purchased</a> a substantial number of shares in Tempus AI despite the company&#8217;s stock falling after reporting mixed fourth-quarter results.
Ark Invest&#8217;s ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) bought 268,467 shares of Recursion Pharmaceuticals and 32,467 shares of Tempus AI.
The ARK Innovation ETF acquired 384,956 shares of Recursion Pharmaceuticals and 49,250 shares of Tempus AI.
Given the closing prices of $56.18 for Tempus AI and $7.51 for Recursion Pharmaceuticals, the total value of these trades is $36.7 million and $0.61 million, respectively.
The IRDM, TWST, ADYEY, ACCD, and EXAS Trades
Ark Invest&#8217;s ARK Innovation ETF bought 73,659 shares of&nbsp;Iridium Communications Inc, while selling 65,290 shares of&nbsp;Twist Bioscience Corp.
The ARK Next Generation Internet ETF sold a small number of shares (52) of&nbsp;Adyen NV.
The ARK Genomic Revolution ETF sold 80,270 shares of&nbsp;Exact Sciences Corp&nbsp;and a minor quantity (232) of&nbsp;Accolade Inc&nbsp;shares.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43900360/bill-gates-has-a-warning-for-the-next-generation-says-be-very-afraid-of-these-4-issues" target="_blank" rel="noreferrer noopener">Bill Gates Has A Warning For The Next Generation, Says Be ‘Very Afraid' Of These 4 Issues</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Ark Invest

ACCD

ACHR

ADYEY

ARKQ

ARKX

IRDM

RXRX

TWST

Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday

Piper Sandler analyst David Westenberg maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and lowers the price target from $75 to $70.

Piper Sandler Maintains Overweight on Exact Sciences, Lowers Price Target to $70

Scotiabank analyst Sung Ji Nam maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Sector Outperform and raises the price target from $70 to $73.

Scotiabank Maintains Sector Outperform on Exact Sciences, Raises Price Target to $73

On Thursday, Guardant Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GH#NYSE">GH</a>) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, beating the <a target="_blank" href="http://during the premarket session on last check Thursday." rel="noreferrer noopener">consensus loss of 74 cents</a>.
The cancer diagnostic company reported sales of $201.8 million, up 30% year over year, beating the consensus of $192.14 million, driven by an increase in the volume of clinical tests and biopharma tests, which grew <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43865627/guardant-health-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-2025-outl" rel="noreferrer noopener">24% and 16%, respectively</a>.
The company reported approximately 57,300 oncology clinical tests (excluding Shield) and 11,050 biopharma tests.
The increase in precision oncology revenue was also attributable to an increase in reimbursement for tests due to an increase in Medicare reimbursement for the Guardant360 LDT test to $5,000 and an increase in both Medicare Advantage and commercial payer reimbursement.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43110223/guardant-health-gains-medicare-coverage-for-colorectal-cancer-monitoring-test" rel="noreferrer noopener">Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test</a>
Guidance: Guardant Health forecasts fiscal year 2025 revenue of $850 million—$860 million, versus a consensus of $848.9 million.
Analyst Reaction:
<ul>
<li>William Blair has recently become more optimistic about Guardant. The stock's momentum could continue, especially if investors trust the company's strategy.</li>
<li>While some gains might slow ahead of Exact Sciences Corp's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) midyear results for its blood-based colorectal cancer screening test, analyst Andrew F. Brackmann writes strong financial performance and Guardant's own data updates will support the stock. William Blair maintains <a href="https://www.benzinga.com/quote/GH/analyst-ratings" target="_blank" rel="noreferrer noopener">the Outperform rating</a>.</li>
<li>Stifel analyst Daniel Arias maintains Guardant Health with a Buy and raises the price target from $45 to $53.</li>
<li>JP Morgan analyst Rachel Vatnsdal reaffirms Guardant Health's Overweight rating and raises the price target from $50 to $55.</li>
<li>Raymond James analyst Andrew Cooper reiterates Guardant Health with an Outperform and raises the price target from $39 to $59.</li>
<li>Goldman Sachs analyst Matthew Sykes maintains Guardant Health with a Buy and raises the price target from $49 to $56.</li>
</ul>
Price Action: GH stock is down 10.60% at $42.40 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43888128/pfizer-discontinues-hemophilia-gene-therapy-beqvez-interest-wanes" target="_blank" rel="noreferrer noopener">Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes</a></li>
</ul>

Analyst Color

Earnings

Guidance

Health Care

Movers

Trading Ideas

General

What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?

During the last three months, 7 analysts shared their evaluations of Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $71.14, a high estimate of $86.00, and a low estimate of $65.00. This current average represents a 0.5% decrease from the previous average price target of $71.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1740081673_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Exact Sciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exact Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Exact Sciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Exact Sciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>All You Need to Know About Exact Sciences</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Exact Sciences's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Exact Sciences displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 12.78%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Exact Sciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -5.4%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Exact Sciences's ROE stands out, surpassing industry averages. With an impressive ROE of -1.19%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exact Sciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.57%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Exact Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.86.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stocks tumbled Thursday, with all major indices in the red, one day after the S&amp;P 500 notched another all-time high in Wednesday&#8217;s trading session. Investors are weighing uncertainty surrounding tariff policies and disappointing guidance from Walmart while digesting new<a href="https://www.benzinga.com/markets/forex/25/02/43843332/global-markets-mixed-dollar-dips-as-traders-react-to-trumps-tariff-plans-global-markets-today-while-us-slept"> initial jobless claims data.</a>
Mega-retailer Walmart, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)&#8217;s shares dropped after the company issued fiscal 2026 guidance below analyst expectations, despite fourth-quarter results beating expectations.
Retail investor darling Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) added to Wednesday&#8217;s declines <a href="https://www.benzinga.com/25/02/43849289/whats-going-on-with-palantir-stock-thursday">following a report </a>that the Trump administration told the Pentagon to prepare for sweeping budget cuts and CEO Alex Karp filed a new trading plan to sell up to $1.2 billion shares.
Read Next:<a href="https://www.benzinga.com/25/02/43836832/trump-administration-orders-sweeping-pentagon-cuts-defense-sector-stocks-on-watch"> Trump Administration Orders Sweeping Pentagon Cuts: Palantir, Lockheed Martin, General Dynamics Among Stocks On Watch</a>
Initial jobless claims rose by 5,000 to 219,000, above expectations of 215,000, while continuing claims rose to 186,900 in the first week of February.
WTI crude oil futures rose above $72 per barrel on Thursday, extending its streak of gains to four days as supply concerns outweighed a rise in U.S. stockpiles, according to TradingEconomics. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.09% to $97,695. The yield on the 10-year US Treasury note pulled back slightly to 4.5%.
<h2 class="wp-block-heading">Thursday's Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,911.27</td>
<td>-0.72%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,101.27 </td>
<td>-0.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,036.44</td>
<td>-1.32%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,252.49</td>
<td>-1.31%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.67% to $608.82. </li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 1.26% at $441.02</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) slipped 0.7% to $535.72. </li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) was down 1.17% to $223.79. </li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) fell 1.39% to $223.10.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)&nbsp;rose 0.6% to $92.57. </li>
</ul>
<h2 class="wp-block-heading">Thursday's Stock Movers:&nbsp;</h2>
Cruise stocks Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) and Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCHL#NYSE">NCHL</a>) tumbled, leading consumer discretionary stocks lower. The SPDR Select Sector Fund &#8211; Consumer Discretionary (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) fell 1.44%. 
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)&nbsp;</li>
<li>Vale S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>)&nbsp;</li>
<li>B2Gold Corp. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTG#AMEX">BTG</a>)</li>
<li>Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)</li>
<li>Alamos Gold Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>)</li>
<li>Walmart, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) </li>
<li>Taseko Mines, Ltd. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TGB#AMEX">TGB</a>)&nbsp;</li>
<li>Shake Shack, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) </li>
<li>Materialise NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) </li>
<li>Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) </li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) </li>
<li>Jumia Technologies AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JMIA#NYSE">JMIA</a>) </li>
<li>Birkenstock Holding Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) </li>
<li>Sabre Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) </li>
<li>Ardelyx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) </li>
</ul>
Companies reporting after Thursday's closing bell include:&nbsp;
<ul>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) </li>
<li>Dropbox, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBX#NASDAQ">DBX</a>) </li>
<li>Iamgold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) </li>
<li>The RealReal, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>) </li>
<li>Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) </li>
<li>Consolidated Edison, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) </li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) </li>
<li>Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) </li>
<li>Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) </li>
<li>MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a></li>
</ul>
Image: Shutterstock.

Market Summary

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Commodities

Econ #s

$BTC

ARDX

BABA

BIRK

BKNG

CELH

CVNA

SPDR Dow Jones Industrial Average ETF Trust

JMIA

MELI

MTLS

NCHL

NCLH

PLTR

REAL

RIVN

SABR

SHAK

VALE

Select Sector SPDR-Consumer Discretionary

Palantir Rally Loses Steam, Walmart Outlook Disappoints: What's Driving Markets Thursday?

WIIM

Exact Sciences shares are trading lower after Barclays and B of A Securities cut their respective price targets on the stock.

B of A Securities analyst Derik De Bruin maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $72 to $65.

B of A Securities Maintains Buy on Exact Sciences, Lowers Price Target to $65

Barclays analyst Luke Sergott maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and lowers the price target from $70 to $65.

Barclays Maintains Overweight on Exact Sciences, Lowers Price Target to $65

Exact Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported fourth-quarter financial results after the market close on Wednesday. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/02/b43829765/exact-sciences-announces-fourth-quarter-2024-results">from the quarter</a>.
Q4 Earnings: Exact Sciences reported fourth-quarter revenue of $713 million, beating analyst estimates of $701.3 million, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>. Total revenue was up 10% on a year-over-year basis. 
Screening revenue totaled&nbsp;$553 million in the quarter, up&nbsp;14% year-over-year. Precision Oncology revenue came in at&nbsp;$161 million,&nbsp;up 0.4% year-over-year.
Exact Sciences generated $47 million of operating cash flow and $11 million of free cash flow during the quarter. The company ended the period with $1.04 billion in cash, cash equivalents and marketable securities.
&#8220;The Exact Sciences team is off to a good start in 2025, building on the momentum we created in the&nbsp;fourth quarter,&#8221; said Kevin Conroy, chairman and CEO of Exact Sciences. 
&#8220;This year is on track to be the most productive in company history, with continued execution from our core business and the launch of three innovative cancer tests. This will power years of growth and profitability, deepen our leadership in diagnostics, and help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment.&#8221;
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/02/43831159/carvana-stock-hits-the-brakes-following-q4-earnings-revenue-beat-eps-beat-upbeat-guidance-this-is-just-the-beginning">Carvana Stock Hits The Brakes Following Q4 Earnings: Revenue Beat, EPS Beat, Upbeat Guidance — &#8216;This Is Just The Beginning&#8217;</a>
Outlook: Exact Sciences expects full-year 2025 revenue to be in the range of $3.03 billion to $3.09 billion. Full-year Screening revenue is expected to be in the range of $2.35 billion to $2.39 billion, and Precision Oncology revenue is expected to be between $675 million and $695 million. 
The company anticipates full-year adjusted EBITDA of $410 million to $440 million, versus $323 million in 2024. 
Exact Sciences executives will further discuss the company&#8217;s quarterly results on a conference call set for 5 p.m. ET.
EXAS Price Action: <a href="https://www.benzinga.com/quote/EXAS" target="_blank" rel="noreferrer noopener">Exact Sciences shares</a> were down 2.2% after hours, trading at $49.36 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Exact Sciences.

After-Hours Center

Exact Sciences Stock Slides On Q4 Earnings: The Details

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported quarterly sales of $713.00 million which beat the analyst consensus estimate of $701.30 million by 1.67 percent. This is a 10.22 percent increase over sales of $646.88 million the same period last year.

Earnings Beats

Exact Sciences Q4 Sales $713.00M Beat $701.30M Estimate

All three major U.S. indices are red in Wednesday's midday trading as investors weighed President Donald Trump's proposed tariffs on auto imports, pharmaceuticals and semiconductors. An official announcement is<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43807804/us-stocks-likely-to-open-lower-following-fresh-records-from-previous-session-expert-says-dont-be-scared-of-new-highs"> expected as soon as April 2.&nbsp;</a>
Markets are anticipating the release of the most recent FOMC minutes later in the trading day which will give further insight into the Federal Reserve's policy outlook. The Fed held interest rates steady at its last meeting and has signaled it is in no hurry to lower rates.&nbsp;
Natural gas futures were up 5%, closing in on a two-year high, as extreme <a href="https://www.benzinga.com/general/travel/25/02/43814828/life-threatening-cold-air-snow-brings-travel-delays-higher-heating-costs">cold temperatures</a> across the U.S. drove higher heating demand and froze oil and gas wells, disrupting production. Adding to the pressure on prices are record-level gas flows to LNG export plants. The United States Natural Gas Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) ETF was up more than 5% midday Wednesday.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/travel/25/02/43814828/life-threatening-cold-air-snow-brings-travel-delays-higher-heating-costs">&#8216;Life-Threatening&#8217; Cold Air, Snow Brings Travel Delays, Higher Heating Costs</a>
The yield on the 10-year US Treasury note held above 4.5% on Wednesday after Trump issued new tariff threats which fueled inflation concerns. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rose 0.03% to $88.13.&nbsp;
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose to above the $96,000 level as crypto markets recovered some of Tuesday's losses.&nbsp;
<h2 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,037.70</td>
<td>-0.02%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,132.74</td>
<td>0.05%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,465.91</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,284.05</td>
<td>0.28%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched up 0.05% to $611.78</li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 0.17% at $445.16. </li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was flat at $539.41. </li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.4% to $226.31.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) dipped 0.38% to $225.52. </li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) rose 1.36% to $92.54. </li>
</ul>
<h2 class="wp-block-heading">Wednesday's Stock Movers:&nbsp;</h2>
Shares of EV truck maker Nikola Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) plummeted after the <a href="https://www.benzinga.com/news/asset-sales/25/02/43811409/nikola-files-for-bankruptcy-seeks-auction-for-sale-of-its-assets">company filed</a> for Chapter 11 bankruptcy, seeking to auction its assets while continuing limited operations through March 2025. Another small EV company, Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>), shares are down after the company reported significant losses in its fourth-quarter earnings release before the opening bell.&nbsp;
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Devon Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)&nbsp;</li>
<li>Bumble, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>)&nbsp;</li>
<li>Shift4 Payments, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>)&nbsp;</li>
<li>Cadence Design Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>)</li>
<li>Medifast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>)&nbsp;</li>
<li>Appian Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>)&nbsp;</li>
<li>Arista Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NASDAQ">ANET</a>)&nbsp;</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>)&nbsp;</li>
<li>Global-E Online Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>)&nbsp;</li>
<li>Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>)&nbsp;</li>
</ul>
Companies reporting after Wednesday's closing bell include:&nbsp;
<ul>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)&nbsp;</li>
<li>Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)&nbsp;</li>
<li>The Cheesecake Factory Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>)&nbsp;</li>
<li>Alamos Gold Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>)</li>
<li>Borr Drilling Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>)&nbsp;</li>
<li>Taseko Mines, Ltd. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TGB#AMEX">TGB</a>)&nbsp;</li>
<li>Equinox Gold Corp.&nbsp; (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EQX#AMEX">EQX</a>)&nbsp;</li>
<li>B2Gold Corp. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTG#AMEX">BTG</a>)&nbsp;</li>
<li>Vale S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>)&nbsp;</li>
<li>Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)&nbsp;</li>
<li>Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>)&nbsp;</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/02/43787369/us-russian-officials-begin-ukraine-peace-talks-defense-sector-stocks-rise"> US, Russian Officials Begin Ukraine Peace Talks: Defense Sector Stocks Rise</a></li>
</ul>
Photo: gary yim/Shutterstock.com

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Treasuries

Federal Reserve

Tech

ANET

APPN

BMBL

BORR

CAKE

CDNS

FOUR

GLBE

GRAB

GRMN

MULN

NKLA

SEDG

iShares Trust Barclays 20+ Year Treasury Bond Fund

TOST

Trump Calls For More Tariffs, Federal Reserve Minutes On Deck: What's Driving Markets Wednesday?

ACVA

AMPL

ANSS

BLCO

BMRN

CCAP

CCSI

CHDN

CLVT

CMTG

CWAN

ENLT

ENVX

ESRT

ETSY

FOLD

First Trust Advantage Preferred Income Fund

FVRR

HSBC

ICLR

IIPR

IMAX

INSG

IONS

KALU

KPTI

KRYS

KVYO

LAND

LILA

LILAK

LOPE

LUNG

MANU

MATV

MGRC

MTRN

NDSN

NRDS

NYMT

OBDC

PAAS

PERI

PNST

PRAA

Earnings Scheduled For February 19, 2025

<a href="https://www.businesswire.com/news/home/20250218781790/en/" title="https://www.businesswire.com/news/home/20250218781790/en/">https://www.businesswire.com/news/home/20250218781790/en/</a>

Legal

US Patent Trial And Appeal Board Institutes Inter Partes Review Of US Patent No. 11,970,746 Owned By Exact Sciences

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RXRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.00</td>
<td>$26.6K</td>
<td>2.5K</td>
<td>4.6K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$20.00</td>
<td>$95.5K</td>
<td>1.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$200.00</td>
<td>$192.0K</td>
<td>55</td>
<td>286</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$153.7K</td>
<td>609</td>
<td>250</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$85.00</td>
<td>$26.1K</td>
<td>2.6K</td>
<td>216</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$50.00</td>
<td>$56.0K</td>
<td>1.3K</td>
<td>201</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$60.00</td>
<td>$40.1K</td>
<td>13.3K</td>
<td>156</td>
</tr>
<tr>
<td>ARWR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$20.00</td>
<td>$27.4K</td>
<td>385</td>
<td>110</td>
</tr>
<tr>
<td>WGS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$77.50</td>
<td>$35.0K</td>
<td>176</td>
<td>46</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$100.00</td>
<td>$35.6K</td>
<td>602</td>
<td>30</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we notice a put option sweep that happens to be bullish, expiring in 35 day(s) on March 21, 2025. This event was a transfer of 533 contract(s) at a $8.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $26.6K, with a price of $50.0 per contract. There were 2587 open contracts at this strike prior to today, and today 4649 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option trade that happens to be bullish, expiring in 336 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $95.5K, with a price of $191.0 per contract. There were 1849 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold. 
• For WST (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), we notice a call option sweep that happens to be bearish, expiring in 308 day(s) on December 19, 2025. This event was a transfer of 40 contract(s) at a $200.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $192.0K, with a price of $4800.0 per contract. There were 55 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• Regarding EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we observe a put option trade with bullish sentiment. It expires in 336 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $153.7K, with a price of $615.0 per contract. There were 609 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option trade that happens to be bullish, expiring in 154 day(s) on July 18, 2025. This event was a transfer of 39 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $26.1K, with a price of $670.0 per contract. There were 2690 open contracts at this strike prior to today, and today 216 contract(s) were bought and sold. 
• For SWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), we notice a call option trade that happens to be bearish, expiring in 7 day(s) on February 21, 2025. This event was a transfer of 50 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $56.0K, with a price of $1120.0 per contract. There were 1300 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bearish sentiment. It expires in 35 day(s) on March 21, 2025. Parties traded 59 contract(s) at a $60.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $40.1K, with a price of $680.0 per contract. There were 13329 open contracts at this strike prior to today, and today 156 contract(s) were bought and sold. 
• For ARWR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>), we notice a call option sweep that happens to be bullish, expiring in 126 day(s) on June 20, 2025. This event was a transfer of 100 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $276.0 per contract. There were 385 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold. 
• Regarding WGS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), we observe a call option trade with neutral sentiment. It expires in 7 day(s) on February 21, 2025. Parties traded 35 contract(s) at a $77.50 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1000.0 per contract. There were 176 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we notice a put option sweep that happens to be bullish, expiring in 336 day(s) on January 16, 2026. This event was a transfer of 30 contract(s) at a $100.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $35.6K, with a price of $1177.0 per contract. There were 602 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ARWR

MRNA

SRPT

SWTX

10 Health Care Stocks With Whale Alerts In Today's Session

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) underwent analysis by 19 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">14</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $73.63, a high estimate of $95.00, and a low estimate of $60.00. This current average has decreased by 5.94% from the previous average price target of $78.28. 
<img src="https://www.benzinga.com/files/images/story/2025/1737655212_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Exact Sciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Alex Nowark</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exact Sciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Exact Sciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Exact Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>Get to Know Exact Sciences Better</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Exact Sciences: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Exact Sciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 12.78%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Exact Sciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.4% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Exact Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Exact Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.57%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Exact Sciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 19 Analyst Projections For Exact Sciences

Barclays analyst Luke Sergott initiates coverage on Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight rating and announces Price Target of $70.

Barclays Initiates Coverage On Exact Sciences with Overweight Rating, Announces Price Target of $70

Press Releases

New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients

Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

Management

Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

Exact Sciences Announces Fourth Quarter 2024 Results

Exact Sciences to Participate in March Investor Conferences

Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening

Comments

Exact Sciences

Vendite allo scoperto

Exact Sciences (NASDAQ:EXAS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO